ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

News

MBCC 2016 hero

News

Despite clinical trial evidence and recommendations that certain older breast cancer patients can forego radiation therapy after lumpectomy, most older patients continue to receive radiation therapy, according to a new study.

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.

A novel prediction model can help predict long-term overall survival among breast cancer patients with distant metastases, according to a new study. The model could be used as a decision-making tool for physicians and patients.

The FDA has granted orphan drug designation for the novel agent known as TRC105, in development by Tracon Pharmaceuticals, for the treatment of soft-tissue sarcoma.

The use of a standard yearly physical examination to screen for thyroid cancer among high-risk survivors of childhood and young adult cancers resulted in a negative predictive value of 100% for clinically relevant thyroid cancer and a significant cost savings compared with regular ultrasound screening.

A median overall survival of longer than 2 years was achieved in a group of patients with metastatic melanoma assigned to treatment with the combination of dabrafenib and trametinib.

Older patients with AML who are ineligible for intensive chemotherapy achieved improved overall survival when assigned to low-dose gemtuzumab ozogamicin.

Pages

Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.